The direct 1,9-dimethylmethyleneblue (DMB) method for quantifyingsulfatedglycosaminoglycan(GAG) in urine (Clin Chem 1989;35:374-9) has been adapted to a convenient meansfor samplecollectionandtransportas a test to identify individualswith mucopolysaccharidosis (MPS) storage diseases. Results correlated moderately well (r = 0.85) with those of a commonly used the underlying metabolic defect. The presence of a serious MPS disease is usually not suspected until nine months to four years of age, when severe physical and (or) neurological manifestations become apparent. Genetic counseling to inform parents of the 25% recurrence risk for future pregnancies is not possible until the initial proband is identified; thus, the formation of families with two or three affected children is an especially unfortunate consequence of the typically "late" diagnosis of MPS disease.
the underlying metabolic defect. The presence of a serious MPS disease is usually not suspected until nine months to four years of age, when severe physical and (or) neurological manifestations become apparent. Genetic counseling to inform parents of the 25% recurrence risk for future pregnancies is not possible until the initial proband is identified; thus, the formation of families with two or three affected children is an especially unfortunate consequence of the typically "late" diagnosis of MPS disease.
Because systemic accumulation probably begins prenatally, excessive glycosaminoglycans are excreted in urine at birth (7) , which could provide a means of early presymptomatic diagnosis. However, technical limitations in measuring urinary glycosaminoglycans are prohibitive, and mass screening of newborns for these conditions has been limited to one early pilot study (8).
Existing test methodologies for diagnosis of MPS conditions require large fresh or frozen urine specimens, which are not routinely obtainable from infants. Recently, we have developed a direct method exploiting the metachromatic reaction of 1,9-diniethylmethylene blue (DMB) dye. The method is applicable to specimens as small as 0.1 mL, provides quantitative results, and obviates the cumbersome and labor-intensive procedures for separating glycosaminoglycans from other constituents of urine (9). However, application of this or any other existing method to test large numbers of newborn infants is currently limited by the difficulties of obtaining, storing, and transporting fresh or frozen urine specimens.
In attempting to solve these problems, we discovered that urinary glycosaminoglycans can be dried onto a paper matrix, stored or mailed, and then eluted into an aqueous solution for quantification by the direct DMB method. As demonstrated by comparison of normal and pathological specimens, this procedure surmounts the major problems inherent to methods requiring fresh or frozen urine specimens, thus providing the technical capability for mass screening of newborn infants.
MaterIals and Methods

DMB dye reagent.
A stock solution containing 0.35 mmol of 1,9-dimethylmethylene blue chloride (no. 03610-1; Polysciences, Inc., Warrington, PA) per liter, the "lOx stock solution," was made by dissolving 122 mg of dye in 10 mL of 95% ethanol, then diluting to 1 L with sodium formate buffer (pH 3.5,0.2 molJL). Stored in an amber-colored bottle at room temperature, this lOx stock solution could be used reliably for as long as two months. For analysis of urine specimens, we prepared a working solution of 105 Mmol/L ("3 x ") dye solution on the day of use by appropriate dilution with the sodium formate buffer.
Collection of urine specimens. For preliminary characterization of methodologies, urine specimens were collected from subjects with MPS diseases and from unaffected individuals, and stored at -20 #{176}C until assay. Aliquots of urine were applied to a paper matrix, approximately 5 mL of urine per 30 cm2 of paper, either 3MM chromatography paper (cat. no. 3030917; Whatman International Ltd., Maidstone, U.K.) or Type 903 specimen-collection paper (cat. no. 15750; Schleicher & Schuell, Inc., Keene, NH). Urine-wetted paper was laid flat on clean plastic wrap and dried overnight under ambient conditions. Specimens dried on paper could be stored indefinitely in a "zip-lock" plastic bag at room temperature.
However, incompletely dried specimens are rapidly discolored by fungal growth and must be discarded; thus complete drying before sealing in the bag is crucial.
For preparation of specimens at home, subjects were instructed to prepare urine specimens in a similar fashion by wetting a piece of Type 903 specimen-collection paper with fresh urine, or by blotting the paper against a urinewet diaper. Alternatively, a piece of specimen-collection paper was inserted between the skin and the front of the diaper, and later removed when damp with urine (taking care to avoid contamination with skin creams or stool). After overnight drying, the specimen-collection paper was placed in a plastic bag and returned to the laboratory by first-class U.S. mail. Three separate urine specimens were obtained from most subjects. AU MPS patients had received an appropriate diagnostic examination by us or, in a few cases, the parents provided sufficient information to establish the medical diagnosis. Each specimen was accompanied by a list of medications taken during the 24 h preceding urine collection. All urine specimens prepared by subjects (or parents) appeared by visual inspection to be satisfactory for study and were analyzed. Glycosaminoglycan standards. Reference solutions of heparan sulfate from bovine kidney (no. H9637), keratan sulfate from bovine cornea (no. K3001), chondroitin sulfate type A from whale cartilage (no. C4134), dermatan sulfate (i.e., chondroitin sulfate type B from porcine skin; no. C4259), and chondroitin sulfate type C from shark cartilage (no. C4384), all from Sigma Chemical Co., St. Louis, MO, were prepared in distilled water and stored at -20 #{176}C.
Elution of urine specimens. To study specimens collected on paper, we cut the specimen-collection paper to a convenient size of 30 cm2 (typically 10 cm x 3 cm), folded this accordion-style, and placed it in a 15-mL polypropylene tube (Falcon no. 2095; Becton Dickinson Labware, Oxnard, CA). We then eluted the urine sample by adding 3.5 mL of distilled water and gently rocking the sample for 10-20 miii. The eluate from paper was assayed for glycosaminoglycan and for creatinune.
When samples were found to have glycosaminoglycan or creatinine concentrations exceeding the limits of linearity for the test reaction, we eluted an appropriately smaller piece of paper (typically 3-fl cm2) with 3.5 mL of distilled water and assayed in the same manner.
Dye-binding assay for glycosaminoglycan. For quantffication of glycosaminoglycan, we added 0.5 mL of the paper matrix eluate to 0.25 mL of "3x" dye reagent. The absorbance of the test reaction was compared with those for standard solutions of chondroitin 6-sulfate (1, 2, 3,... 10 zg/mL). Eluates with high concentrations of glycosaminoglycan were diluted 10-fold with distilled water, then assayed in the usual test reaction. Duplicate aliquots of each eluate from paper were assayed, and the result was reported as the mean of these two values.
Creatinine assay. Creatinine was determined according to our modification of the method of Jaff#{233}. We mixed 0.25 mL of paper eluate with 1.0 mL of 20% saturated picric acid (fivefold-diluted saturated picric acid solution, no. 925-40, 
Results
Developmentof Standard Assay Conditions
As a means of conveniently obtaining, transporting, and storing specimens of urine from large numbers of subjects, a method of collecting urine onto a paper matrix was examined. To determine conditions that would allow recovery and quantification of urinary glycosaminoglycans on a routine basis, we initially studied the reactivity of DMB dye with the paper matrix material, and evaluated recovery of glycosaminoglycan reference solutions. Inertness of paper matrix to dye. When virgin paper matrix was soaked with "3x" DMB dye reagent, both the paper matrix and the aqueous phase retained the blue color of unreacted dye and showed no change to the violet color of glycosaminoglycan-DMB (GAG-DMB) complexes. However, because the paper was stained blue when removed from dye solution, it was presumed that nonspecific binding could potentially interfere with quantitative GAG-DMB formation; therefore, development of a quantitative in situ method was abandoned and elution of glycosauninoglycans from the paper matrix was investigated.
Virgin paper matrix material was soaked in 3.5 mL of distilled water, and then aliquots of the eluate were mixed with 1 mL of DMB dye reagent. There was no visible color change and no increase in absorbance (at 535 nm) over the appropriate blank. Thus, although DMB dye appeared to adsorb onto paper, the paper matrix was otherwise inert to DMB dye and did not produce a change in absorbance at the appropriate wavelength.
Time course of elution of solutes from paper matrix. Further to characterize recovery of glycosaminoglycan and creatinine from a paper matrix, we applied solutions of chondroitun 6-sulfate and creatinine to 3 x 10 cm pieces of specimen-collection paper, dried them overnight, and then eluted with distilled water for specified times. Creatinune dissolved quickly, being maximally eluted within 30 s, whereas chondroitin 6-sulfate was more slowly removed into solution. Both glycosaminoglycan and creatinine were maximally eluted within 10 to 20 mm, which was chosen as a convenient elution interval for subsequent studies. Quantitative recovery of glycosaminoglycan from paper matrix. Quantitative recovery of different glycosaminoglycan species from specimen-collection paper was studied. Glycosaminoglycan reference solutions were applied to 3 x 10 cm paper strips, dried overnight, and then eluted with 3.5 mL of distilled water. Recovery from Type 903 specimen-collection paper was found to be proportional to the amount applied, although recovery (quantified against the usual chondroitin 6-sulfate reference solution) varied with the GAG (dermatan sulfate 104%, heparan sulfate 86%, and keratan sulfate 73%). Similar results were obtained when the same heparan sulfate, dermatan sulfate, and keratan sulfate reference solutions were applied to and eluted from Whatman 3MM laboratory chromatography paper, suggesting that quantitative recovery of glycosaminoglycan from paper matrix is a generalized phenomenon. As a means of providing an internal physiological standard, we studied the extraction of creatimne reference solutions in a similar fashion and found recovery of creatmine to be complete.
Precision evaluation.
Reproducibility of this method of collection, elutiom, and manual quantification was assessed by adaptation of the precision performance evaluation protocol as described for comparison of clinical chemistry instrumentation (10). For this evaluation, we prepared three concentrations of urinary glycosaminoglycan that extended over the range of anticipated normal and pathological specimens: a single, large urine sample from a normal adult was analyzed unaltered (i.e., "low" glycosaminoglycan) or after supplementation with additional chondroitin 6-sulfate in moderate (i.e., "intermediate") or "high" concentration.
Multiple specimens of each concentration were dried on the paper matrix and serially tested in 40 separate repetitions or "runs" dome during two months (Table 1) . Under these standard assay conditions the coefficient of variation (CV) was found to range from 10.2% to 20.1%. It was not surprising that reproducibility was best for the intermediate and high values, insofar as our preliminary studies (not described here) adjusted reaction conditions for the range of glycosaminoglycan excretion by children and newborn infants. For other applications, reaction conditions could be readily adjusted to maximize reproducibility at other levels of glycosaminoglycan excretion as required.
Table 1. Summary of PrecIsIon Performance EvaluatIon
Glyco.amlnoglyc.n "sxcrMlon" a A precision performance evaluation was accomplished by adaptation of the protocol described for companson of clinical chemistry Instrumentation (.eference 10, wIth modifications according to Appendix C). FortyIndependent runs, performedovera two-monthperiod,determined GAG/creatinineratio in two specimens prepared from each of the three controls (low, Intermediate, high). The measurement on each specimen was the mean of duplicateassays described In MateriaLs and Methods.
b Total precision standard deviation (SD,-) as defined (10).
Application to Unne Specimens
Comparison with CPC/carbazole methodology. The direct DMB method applied to paper-matrix eluate, i.e., the "paper matrix/DMB method," was compared with the commonly used quantitative procedure of Bitter and Muir (11) as modified by Di Ferrante (12), i.e., overnight precipitation with cetylpyridinium chloride (CPC) and quantification of uronic acid with carbazole reagent. For this comparison, we analyzed by each method 33 urine specimens covering the range of normal and pathological glycoaaminoglycan concentrations.
As shown in Figure 1 , results by the two methods agreed closely with respect to the glycosaminoglycan/creatmnine ratio (r = 0.85). Rapid quantification of un nary glycosaminoglycan excretion in MPS. As shown in Table 2 , a relatively large number of normal subjects and MPS patients could be studied, owing to the convenience of obtaining and transporting specimens with the paper-matrix system. Glycosaminoglycan excretion in normal individuals was highly variable with respect to age. As illustrated in Figure 2 , trials of several curve-fitting calculations suggested that the data best fit a logarithmic function, with a marked inflection near age five years. Inspection of the results for measured glycosaminoglycan excretion by the group of MPS patients (Table 2 ) suggests a similar trend, which is somewhat masked by the very high concentrations of glycosaminoglycan.
We presume that the trend in both groups (normal subjects and MPS patients) is attributable to age-related differences in creatinine excretion and to I-HS) . "Aliquot of a 24-h urine collection was dried onto paper matrixin the laboratory(in contrast to all other specimens, which were preparedat home from a single-void grab' urine specimen, dried overnight, and then transported to the laboratory by mall).
C Two subjects with nori-MPS types of skeletaldysplasiahad somewhat greater glycosaminoglycan excretion but were readily distinguishable from the more markedly increased amounts characteristic of MPS disease. Urinary glycosaminoglycan excretion by normal infants. To evaluate the applicability of this method for testing large numbers of infants, and to establish the range of glycosaminoglycan excretion in this population, we applied the paper matrix/DMB method to a single specimen collected from each of 435 infants. These specimens were obtained at three weeks of age. As seen from the frequency distribution (Figure 3 ), this population of presumed-normal three-week-old infants had a mean glycosaminoglycan excretion of 179 (SD 86.3) mg of GAG per gram of creatinine.
Discussion
Inadequacies of existing methods. For any screening test, sample collection must be simple and the analytical technique must be inexpensive, sensitive, and reliable (13). Despite numerous studies describing putative "screening" tests for MPS diseases, no such test currently is routinely applied to any large population because, in part, no test fulfills these requisites. A review of available methods for testing for MPS diseases is characterized by inadequacies (14), especially as they might be applied to the presymptomatic evaluation of large numbers of newborn infants (Table 3) . Most existing tests require a relatively large urine specimen, 1-10 mL, which cannot be routinely obtained from infants (13). For most tests, results are either qualitative or semiquantitative and are subject to limited interpretation.
Only a few methods yield quantitative results from which "positive/negative" limits can be assigned, thus permitting convenient definition of acceptable falsepositive and false-negative error rates based on population data and cost-effectiveness considerations (20) . Existing quantitative methods are labor-intensive and correspondingly expensive and impractical for mass screening of newborns. Only one test, the "direct DMB method" we previously reported (9), surmounts all of these problems.
Importantly, all existing tests, including the direct DMB method, require a fresh or frozen-stored liquid urine specimen. This remains a paramount impediment to actual implementation of a mass newborn screening program. However, as developed in this study, application of the direct DMB method to a convenient sample collection system provides a solution to this problem.
Glycosaminoglycan-binding to paper matrix. The convenience in obtaining, storing, and transporting urine specimens on a paper matrix was first demonstrated by Berry et al. (21) . The system was subsequently adapted to screening newborn infants for other metabolic diseases (22) and is now used routinely in the few existing urine-based newborn screening programs for metabolic diseases (13, 20). The difficulty in extending this strategy to testing for MPS diseases is related to recovering glycosaminoglycan from the paper matrix, and to obtaining quantitative results. In reviewing the Berry system for collecting urine specimens on paper, Scriver (13) suggested that urine-impregnated paper could be subjected to a variety of in situ "spot" tests on specimen-collection paper. He also suggested that urine might be eluted from urine-impregnated paper for analysis in solution. Several disorders can be identified from such dried urine specimens, but to the best of our knowledge, quantitative elution of glycosaminoglycan from specimencollection paper has never been reported.
Whereas the ability to recover amino acids, organic acids, creatinine, and other metabolites from paper matrix has been well established, the difficulties in eluting glycosaminoglycan are implicit in several existing laboratory methods that actually depend upon tight binding of glycosaminoglycan to paper matrix material. For example, the toluidine blue 0 spot test (7, 23) or the "Berry spot test" requires that measured aliquots of urine be applied to a paper matrix, dried, and then reacted in situ with toluidine blue. Glycosaminoglycan-dye complexes remain bound to the paper matrix to permit satisfactory visual observations. Analogously, the "alcian blue spot test" (24) requires that urinary glycosarninoglycan is similarly applied to and dried on a paper matrix. The bound glycosaminoglycan is then reacted in situ with dye. Positive tests are those for been impregnated with azure A dye. After excess dye and other soluble components are washed away, the colored glycosaminoglycan-dye complexes that remain bound to the paper matrix are detectable as a positive result. On the basis of these observations, it was apparent from the outset of our work that urinary glycosaminoglycans are readily bound to paper matrix (possibly by the same cellulosic hydrogen-bonding that is responsible for the basic integrity of paper matrix). It seemed unlikely that urinary glycosaminoglycans dried on a paper matrix could be recovered for quantification in the direct DMB method. To investigate the potential for measuring urinary glycosaminoglycan excretion with this system, we initially attempted to measure glycosaminoglycans in situ on paper matrix by directly adding dye reagent solution. However, we were discouraged from pursuing an in situ test when we observed the blue staining of paper matrix material, which we presumed would interfere with the quantification.
Elation of glycosaminoglycan from paper matrix. As an alternative approach to developing an in situ method, we investigated the potential for eluting dried glycosamino-______________________________________ glycan back into solution for quantification with the direct DMB method. It was quickly determined that various salts alter the formation of GAG-DMB complexes (data not which glycosaminoglycan-dye complexes are visibly retained on the paper matrix after the paper matrix is thoroughly rinsed with glacial acetic acid and then with water. For Ames' "MPS Papers spot test" (25) , a urine specimen is added to squares of paper matrix that have (29, 30) , rely upon quantification of precipitable glycosaminoglycans.
In contrast, the direct DMB method (and this adaptation to the paper matrix collection system) should measure all sulfated glycosaminoglycans, including any relatively small species that might escape precipitation. This would be especially important if some MPS patients excrete smaller species that might not be detected by precipitation methods. For this reason, the direct DMB method may better discriminate normal from MPS specimens as suggested by our earlier comparison of the two methods (see reference 9, Figure 3) . Nevertheless, our comparison of the present method with the cetylpyridimum chioride/carbazole method by simultaneous testing of 33 specimens (Figure 1) showed a good correlation of quantitative results (r = 0.85). In a pilot study, results obtained with the new method revealed that urinary excretion of GAG, when assessed in terms of the ratio of GAG to creatinine, is highly age dependent, both in normal subjects and in patients with MPS diseases. Variation with respect to age has been noted by other investigators using different test methods (19,28) but was presumed to be due to the age-dependent excretion of glycosaminoglycan;
this was described as a simple linear relationship with respect to age (28). In contrast, onr attempts at curve-fitting suggested that this variation in normal individuals best fits a logarithmic function ( Figure  2) , probably owing to changes in creatinine excretion as well as to increased proteoglycan turnover during growth. Because the relationship is logarithmic, with a dramatic inflection during early childhood, it must be recognized that attempts at newborn screening would be especially dependent upon age-specific normative values. This report presents the first such data for a large number of newborn infants (Figure 3) , a study that was feasible only owing to development of the paper matrixfDMB method of specimen collection, elution, and quantification.
The use of single-void "grab" urine specimens from normal individuals has been criticized because of sampleto-sample changes in the type of glycosaminoglycan excreted (31) and circadian periodicity in excretion (32) . The ease of sample collection and analysis with the present method permitted us to study multiple single-void specimens to address this issue. Despite this sample-to-sample variation in normal individuals, results for MPS patients were consistently different from the age-specific normal reference interval.
False-negative results for patients with Sanfilippo's syndrome may be a relatively common problem with existing methods (33). The present test detected somewhat lower values of glycosaminoglycan excretion in patients with Sanfilippo's syndrome compared with other MPS conditions. However, values were markedly increased compared with those for age-appropriate controls, and therefore were easily distinguished from normal. The importance of age-specific comparison is particularly acute for detection of Morquio's syndrome. Humbel and Etringer (34) reported a visual color-change screening test involving the use of DMB dye, but they observed that patients with Morquio's syndrome gave many false-negative results. In contrast to their observations, we found the DMB dye to be highly reactive with keratan sulfate. Furthermore, our new quantitative method should identi1r most, if not all, patients with Morquio's syndrome when age-specific normative data are used. As seen in Table 2 , patients with Morquio's syndrome had values that were not distinguishable from the overall "normal range." However, compared with age-specific values, affected patients were readily distinguished.
One affected child, 3.26 years of age, had values exceeding the age-specific upper limit of normal by severalfold.
Similarly, a 27-year-old patient with Morquio's syndrome had a mean value of 26 mg/g (n = 3) that exceeded by more than twofold the age-specific normal range (for age >20 years, the normal reference interval is 6-12 mg/g). The quantitative distinction between some patients with Morquio's syndrome and normal individuals may be less than for other MPS conditions, but our test does permit differentiation that is not possible by other methods.
Diagnosis of non-MPS skeletal dysplasias. Application of this method may also extend to other conditions previously undetectable by urine testing. We have recently studied one patient with mucolipidosis (ML) type III who, by usual methods (i.e., negative Berry spot test), was found to have normal urinary glycosaminoglycan excretion. However, by our method, this patient showed somewhat increased GAG excretion (mean of three determinations at 4.14 years of age: 57 mg/g). On the basis of this observation, we propose that I-cell disease (MLII) and pseudo-Hurler polydystrophy (ML III), which present with MPS clinical features, might be considered partial defects in glycosaminoglycan catabolism resulting in minimally increased glycosaminoglycan excretion-not previously appreciated owing to the limitations of existing test methods. Analogously, a 2.9-year-old patient with acromesomelic dysplasia (35, 36) had values twofold those for age-appropriate norms (mean of three specimens was 70 mg/g; the range for normal subjects two to five years of age was 17-38 mg/g). At least one patient with this rare non-MPS disorder has had a positive Berry spot test (31). Our patient studied here had "normal" glycosaminoglycan excretion as determined by the method of Bitter and Muir (11). Thus, the present test may permit earlier recognition and differentiation of non-MPS diseases whose presumed aberrant proteoglycan metabolism is revealed by minimally increased GAG excretion.
Normal glycosaminoglycan excretion by newborns. Other studies have demonstrated that urinary glycosaminoglycan excretion is increased in MPS patients even at birth (7) . Thus, the approach of evaluating newborn infants at three weeks of age, which has become a general practice for other metabolic diseases (13, 20) , might be feasible for MPS diseases. Age-specific normative data will be required to diagnose newborns.
For the first time, such data were obtained by testing 435 infants with this new method (Figure 3) . In summary, the unique contribution of this study was the development of a method for recovering and precise quantification of very small amounts of glycosaminoglycan in a fashion applicable to the paper matrix collection system. The method of analysis is rapid with a specimen turnaround time of <2 h. Common laboratory instrumentation is used, and the reagents are readily available, inexpensive, and stable at room temperature without special precautions. In combination, these features make this method readily adaptable to automation.
Nevertheless, manual techniques were used in pilot evaluations to test a variety of normal subjects and patients affected with each of the MPS diseases. As demonstrated in this study, urine specimens can be readily collected by nontechnical personnel (e.g., parents) and conveniently transported to a central testing facility by regular mail. In contrast to most existing screening methods, which are semiquantitative at best, this is a precisely quantitative technique and thereby provides a means for defining specific positive/negative limits based on population data, and the technique can be varied depending upon the requirements and facilities of any particular screening program. With this novel method, we anticipate that all newborns could be tested for MPS disease on a regular basis. Identification of newborn infants with MPS conditions will obviate the diagnostic conundrums presented by MPS disease (e.g., recurrent ear infections, airway obstruction, macrocephaly, linear growth failure, etc.), facilitate more efficient and specific clinical management, enable genetic counseling before the next pregnancy, and facilitate presymptomatic treatment.
